Human CD30 Ligand/TNFSF8 Alexa Fluor® 350-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB1028U
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Gln63-Asp234
Accession # P32971
Specificity
Clonality
Host
Isotype
Applications for Human CD30 Ligand/TNFSF8 Alexa Fluor® 350-conjugated Antibody
Flow Cytometry
Sample: Human peripheral blood mononuclear cells (PBMCs) treated with PMA and Calcium Ionomycin
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: CD30 Ligand/TNFSF8
CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a costimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. Human and mouse CD30 ligand cDNAs share 70% sequence homology.
References
- Brunangelo, F. et al. (1995) Blood 85:1.
- Gruss, H.-J. and F. Herrmann (1996) Leukemia and Lymphoma 20:397.
- Chiarle, R. et al. (1999) J. Immunol. 163:194.
Alternate Names
Gene Symbol
UniProt
Additional CD30 Ligand/TNFSF8 Products
Product Documents for Human CD30 Ligand/TNFSF8 Alexa Fluor® 350-conjugated Antibody
Product Specific Notices for Human CD30 Ligand/TNFSF8 Alexa Fluor® 350-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only